WEDI extends free membership

The Workgroup for Electronic Data Interchange (WEDI) will extend free membership for all federal and state government agencies and their corresponding departments as part of its efforts to spur improvements in health information exchange.

Through the new membership program, government agencies will have free access to participate in approximately 40 workgroups offered by WEDI on health IT topics, WEDI’s public forums and WEDI virtual events, officials said. The agencies also will receive discounted rates to WEDI’s on-site conferences.

All federal and state government agencies and departments will be provided access to WEDI's resources including whitepapers, issue briefs, webinars, networking opportunities, industry best practices and updates on regulatory, legislative and standards changes.

Membership also offers the opportunities to influence the direction of health IT policy through WEDI’s Policy Advisory Groups, officials said.

“Government agencies are a critical partner in our common goal to streamline healthcare information exchange in order to improve the overall efficiency and quality of the American healthcare system”, said Devin Jopp, WEDI's president and CEO, in a statement. "The free government agency membership will provide greater opportunities for the states to benefit from industry best practices and will offer them a greater voice in helping to shape the future of health IT policy."


WEDI’s members include providers, hospitals, health plans, laboratories, pharmacies, clearinghouses and vendors. For more information about WEDI membership, click here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.